Insight into pharmaceutical deals and trends
Get insights into the latest deals and deal trends from Pharma Intelligence. Understand the implications of recent deals as they relate to drug development, reimbursement, and beyond.
18 Total results for product and free and sample content found
By Brian Yang 18 Oct 2019
Multinationals are feeling the heat to win in China's latest drug procurement battle. The winning prices have surprised even previous winners and may have a profound and long-lasting impact on the pharma sector.
24 Jul 2019
Outlook 2020 is the annual look at the performance and future prospects of the global pharmaceutical industry. This year, the supplement will reach more people than ever before with distribution to In Vivo, Pink Sheet, Scrip, Medtech Insight and Generics bulletin subscribers PLUS events such as Biotech Showcase and Partnerships in Clinical Trials.
15 Jul 2019
Get expert insights into the events driving drug pricing polices around the world. This Article Pack covers drug pricing issues for: The EU - Vital developments for Norway, Denmark, and other EU countries, including the UK The US – Essential drug pricing info from a country where the issue has taken center stage Australia – Developments surrounding drug pricing issues in Australia
15 Jul 2019
Our latest whitepaper lists the top selling drugs last year, who developed them and the strategies behind their success. We drew from three of our top products to create our most recent whitepaper, Datamonitor Health Care, Biomedtracker and Pharmaprojects. You can experience them all for yourself.
By Francesca Bruce 05 Jul 2019
Latin American joint price negotiations have proved successful and other countries are taking note.
By Joseph Haas 03 Jul 2019
Looking back at the second quarter, PharmaVitae analysts have selected 10 biopharma companies with market caps under $3bn they think are primed for acquisition – and the likely candidates for a buy-out.
By Penelope MacRae 02 Jul 2019
India’s Supreme Court has told Malvinder Singh and Shivinder Singh, once corporate billionaires, to work out a strategy within two weeks to pay Japanese drug giant Daiichi Sankyo a $500m arbitration award and "uphold the nation’s honor."
By Ljlal Syed, Mark Lansdell and David Abramson 17 May 2018
This report examines the extent to which order of market entry influences the prospects of achieving a satisfactory return on investment for companies developing branded generic
Topic Deal trends
16 Sep 2017
Royalty payments are an essential component of most pharmaceutical deals. Along with upfront payments and milestones, companies are rewarded for surpassing certain developmental hurdles.
No Records Found
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: